CN113924316A - 抗cd25抗体及其应用 - Google Patents

抗cd25抗体及其应用 Download PDF

Info

Publication number
CN113924316A
CN113924316A CN202080000963.5A CN202080000963A CN113924316A CN 113924316 A CN113924316 A CN 113924316A CN 202080000963 A CN202080000963 A CN 202080000963A CN 113924316 A CN113924316 A CN 113924316A
Authority
CN
China
Prior art keywords
antibody
antigen
igg1
cancer
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080000963.5A
Other languages
English (en)
Other versions
CN113924316B (zh
Inventor
宋德勇
刘秀
韩静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Boan Biotechnology Co Ltd
Original Assignee
Shandong Boan Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Boan Biotechnology Co Ltd filed Critical Shandong Boan Biotechnology Co Ltd
Publication of CN113924316A publication Critical patent/CN113924316A/zh
Application granted granted Critical
Publication of CN113924316B publication Critical patent/CN113924316B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明提供一种结合CD25的抗体或其抗原结合片段及其在制备癌症治疗药物中的用途，该抗体或其抗原结合片段包含含有特定互补决定区序列的轻链可变区和重链可变区。该抗体或抗原结合片段具有以下一种或多中优势：增强的CD25蛋白结合能力、增强的CD25蛋白亲和力、增强的CD25表达细胞杀伤能力、减弱的PBMC的激活抑制性、增强的体内肿瘤生长抑制能力、增强的体内肿瘤杀伤能力、增强的减少Treg细胞数量的能力，或增强的增加效应T细胞数量的能力。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080000963.5A 2019-06-10 2020-06-08 抗cd25抗体及其应用 Active CN113924316B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910495626 2019-06-10
CN2019104956267 2019-06-10
CN2019104956144 2019-06-10
CN201910495614 2019-06-10
PCT/CN2020/094919 WO2020248938A1 (zh) 2019-06-10 2020-06-08 抗cd25抗体及其应用

Publications (2)

Publication Number Publication Date
CN113924316A true CN113924316A (zh) 2022-01-11
CN113924316B CN113924316B (zh) 2022-06-21

Family

ID=73780655

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080000963.5A Active CN113924316B (zh) 2019-06-10 2020-06-08 抗cd25抗体及其应用

Country Status (9)

Country Link
US (1) US20220195055A1 (zh)
EP (1) EP3932949A4 (zh)
JP (1) JP7245358B2 (zh)
KR (1) KR20220007120A (zh)
CN (1) CN113924316B (zh)
AU (1) AU2020293160B2 (zh)
BR (1) BR112021024826A2 (zh)
CA (1) CA3135992C (zh)
WO (1) WO2020248938A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024175020A1 (en) * 2023-02-22 2024-08-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-il2ra antibodies and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170626A1 (en) * 2002-11-15 2004-09-02 Genmab, Inc. Human monoclonal antibodies against CD25
US20080317746A1 (en) * 2005-06-01 2008-12-25 Micromet Ag Anti-Il2 Antibodies
US20200010554A1 (en) * 2017-03-17 2020-01-09 Tusk Therapeutics Ltd. Fc-optimized anti-cd25 for tumor specific cell depletion
US20200140538A1 (en) * 2017-05-25 2020-05-07 Institute For Basic Science Anti-human interleukin-2 antibodies and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
CN103571872B (zh) 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 一种能够表达人抗体的转基因动物的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170626A1 (en) * 2002-11-15 2004-09-02 Genmab, Inc. Human monoclonal antibodies against CD25
US20080317746A1 (en) * 2005-06-01 2008-12-25 Micromet Ag Anti-Il2 Antibodies
US20200010554A1 (en) * 2017-03-17 2020-01-09 Tusk Therapeutics Ltd. Fc-optimized anti-cd25 for tumor specific cell depletion
US20200140538A1 (en) * 2017-05-25 2020-05-07 Institute For Basic Science Anti-human interleukin-2 antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROLAND MARTIN: "Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis", 《NEURODEGENER DIS》 *

Also Published As

Publication number Publication date
BR112021024826A2 (pt) 2022-01-25
WO2020248938A1 (zh) 2020-12-17
US20220195055A1 (en) 2022-06-23
EP3932949A4 (en) 2022-06-29
EP3932949A1 (en) 2022-01-05
JP2022527651A (ja) 2022-06-02
CN113924316B (zh) 2022-06-21
KR20220007120A (ko) 2022-01-18
AU2020293160A1 (en) 2021-10-07
CA3135992A1 (en) 2020-12-17
JP7245358B2 (ja) 2023-03-23
CA3135992C (en) 2024-02-13
AU2020293160B2 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
JP7192092B2 (ja) 抗ヒトｃｌａｕｄｉｎ１８．２モノクローナル抗体及びその使用
JP2020182492A (ja) 抗ｃｄ１３７抗体
CN115819585B (zh) 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
US20220213195A1 (en) BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGFß AND USE THEREOF
US20190263905A1 (en) ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
CN113508139A (zh) 结合人lag-3的抗体、其制备方法和用途
CN113924316B (zh) 抗cd25抗体及其应用
WO2020038404A1 (zh) 抗人claudin 18.2单克隆抗体及其应用
CN113402607B (zh) 一种抗lap单克隆抗体、其抗原结合片段及其应用
EP4386000A1 (en) Recombinant anti-human-cd25 antibody and use thereof
CN113754770B (zh) 一种特异性结合人ctla4的抗体及包含其的药物和试剂盒
CN111344305A (zh) 抗pd-l1的抗体及其用途
US20230086530A1 (en) Human cd47-targeting single-domain antibody and use thereof
TW202227504A (zh) 抗ｅｒｂｂ３抗體或其抗原結合片段及其醫藥用途
CN112062848B (zh) 抗cd47单克隆抗体及其应用
WO2023187460A1 (en) Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function
CN118496360A (zh) 一种Claudin18.2抗体及其应用
CN115109157A (zh) 抗体或其抗原结合片段，其制备方法及医药用途
TW202227486A (zh) 一種抗erbb3受體的抗體或其抗原結合片段及其醫藥用途
CN117510636A (zh) Gprc5d抗体及其应用
CN115819582A (zh) Pvrig的抗体或其抗原结合片段及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant